These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 27084108

  • 1. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A, Juhasz K, Thomas U, Stölzle-Feix S, Becker N, Dörr L, Beckler M, Bot C, George M, Fertig N.
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [Abstract] [Full Text] [Related]

  • 2. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X, Guo L, Zeng H, White SL, Furniss M, Balasubramanian B, Lis E, Lagrutta A, Sannajust F, Zhao LL, Xi B, Wang X, Davis M, Abassi YA.
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [Abstract] [Full Text] [Related]

  • 3. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
    Bot CT, Juhasz K, Haeusermann F, Polonchuk L, Traebert M, Stoelzle-Feix S.
    J Pharmacol Toxicol Methods; 2018; 93():46-58. PubMed ID: 29940218
    [Abstract] [Full Text] [Related]

  • 4. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y, Vargas HM.
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [Abstract] [Full Text] [Related]

  • 5. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Washio I, Takahashi E, Miyamoto K, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Kunimatsu T.
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [Abstract] [Full Text] [Related]

  • 6. Resolving the Reversed Rate Effect of Calcium Channel Blockers on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and the Impact on In Vitro Cardiac Safety Evaluation.
    Zeng H, Wang J, Clouse H, Lagrutta A, Sannajust F.
    Toxicol Sci; 2019 Feb 01; 167(2):573-580. PubMed ID: 30365015
    [Abstract] [Full Text] [Related]

  • 7. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
    Altomare C, Pianezzi E, Cervio E, Bolis S, Biemmi V, Benzoni P, Camici GG, Moccetti T, Barile L, Vassalli G.
    Europace; 2016 Dec 01; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.
    Dempsey GT, Chaudhary KW, Atwater N, Nguyen C, Brown BS, McNeish JD, Cohen AE, Kralj JM.
    J Pharmacol Toxicol Methods; 2016 Dec 01; 81():240-50. PubMed ID: 27184445
    [Abstract] [Full Text] [Related]

  • 10. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
    Ando H, Yoshinaga T, Yamamoto W, Asakura K, Uda T, Taniguchi T, Ojima A, Shinkyo R, Kikuchi K, Osada T, Hayashi S, Kasai C, Miyamoto N, Tashibu H, Yamazaki D, Sugiyama A, Kanda Y, Sawada K, Sekino Y.
    J Pharmacol Toxicol Methods; 2017 Dec 01; 84():111-127. PubMed ID: 27956204
    [Abstract] [Full Text] [Related]

  • 11. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B.
    J Cardiovasc Electrophysiol; 2004 Nov 01; 15(11):1302-9. PubMed ID: 15574182
    [Abstract] [Full Text] [Related]

  • 12. Proarrhythmic risk assessment using conventional and new in vitro assays.
    Goineau S, Castagné V.
    Regul Toxicol Pharmacol; 2017 Aug 01; 88():1-11. PubMed ID: 28506844
    [Abstract] [Full Text] [Related]

  • 13. Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.
    Zeng H, Roman MI, Lis E, Lagrutta A, Sannajust F.
    J Pharmacol Toxicol Methods; 2016 Aug 01; 81():217-22. PubMed ID: 27222351
    [Abstract] [Full Text] [Related]

  • 14. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N.
    J Pharmacol Toxicol Methods; 2017 Aug 01; 85():73-81. PubMed ID: 28163191
    [Abstract] [Full Text] [Related]

  • 15. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y, Honda Y, Tsujimoto S, Watanabe H, Kunimatsu T, Funabashi H.
    Toxicol Appl Pharmacol; 2014 Jul 01; 278(1):72-7. PubMed ID: 24742750
    [Abstract] [Full Text] [Related]

  • 16. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.
    da Rocha AM, Creech J, Thonn E, Mironov S, Herron TJ.
    Toxicol Sci; 2020 Feb 01; 173(2):402-415. PubMed ID: 31764978
    [Abstract] [Full Text] [Related]

  • 17. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
    Crumb WJ, Vicente J, Johannesen L, Strauss DG.
    J Pharmacol Toxicol Methods; 2016 Feb 01; 81():251-62. PubMed ID: 27060526
    [Abstract] [Full Text] [Related]

  • 18. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
    Navarrete EG, Liang P, Lan F, Sanchez-Freire V, Simmons C, Gong T, Sharma A, Burridge PW, Patlolla B, Lee AS, Wu H, Beygui RE, Wu SM, Robbins RC, Bers DM, Wu JC.
    Circulation; 2013 Sep 10; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
    [Abstract] [Full Text] [Related]

  • 19. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
    Gibson JK, Yue Y, Bronson J, Palmer C, Numann R.
    J Pharmacol Toxicol Methods; 2014 Sep 10; 70(3):255-67. PubMed ID: 25219538
    [Abstract] [Full Text] [Related]

  • 20. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM.
    J Pharmacol Toxicol Methods; 2013 Sep 10; 68(1):97-111. PubMed ID: 23702537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.